Trial Profile
Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 May 2015
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Malignant carcinoid syndrome; Neuroendocrine carcinoma
- Focus Therapeutic Use
- 28 May 2015 New trial record